Dr Bernhard Helk | Global Executive Director, Technology Development
Novartis

Dr Bernhard Helk, Global Executive Director of Technology Developmen, Novartis

Bernhard Helk is Global Executive Director of Technology Development at Novartis Biologics/Process Sciences. He received a masters degree in Pharmaceutical Sciences from University of Erlangen/Germany and a Ph. D. in Biochemistry from University of Bayreuth/Germany. He performed postdoctoral research with Prof. U.L. RajBhandary at MIT. At Novartis, Dr. Helk has held positions of increasing responsibility in the area of analytics and development of therapeutic proteins. His research interest includes folding, purification, characterization, and stabilization of proteins. Currently, Dr. Helk is leading a unit that searches and evaluates new technologies related to manufacturing and formulation of proteins for pharmaceutical applications. He is also leading several collaborations with industrial and academic partners aimed at the development of disruptive new technologies.

Dr Bernhard Helk @ other events

Appearances at this years' conference:

Conference Day 2: 21 March 2012

@ 11.15

Developability Index: A Rapid In Silico Tool for the Screening of Antibody Aggregation Propensity

Evaluating current methods for in silico prediction of aggregation propensities
Developing a new technology: SAP (Spatial Aggregation Propensity) technology by Novartis and MIT
Mapping the possible applications of the SAP technology and demonstrating its use in protein engineering and in designing antibody drug conjugates